Announcement

Collapse
No announcement yet.

A Review of 18 Companies That Have the Ability to Make a Difference in the Stem Cell

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    A Review of 18 Companies That Have the Ability to Make a Difference in the Stem Cell

    http://www.marketwatch.com/news/news...tegories=&
    A Review of 18 Companies That Have the Ability to Make a Difference in the Stem Cell Industry
    1/23/2006 1:15:01 PM

    DUBLIN, Ireland, Jan 23, 2006 (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/reports/c31288 ) has announced the addition of Stem Cell Companies: 18 Lead the Way to their offering.

    Many companies have jumped on the stem cell band wagon, but only a few are truly performing breakthrough research in the area. This report identifies the 18 companies world-wide that have the potential to make a difference and explores their technologies and likelihood of success. Each company's research and clinical trial pipeline as well as the successes and failures are examined. An additional 14 companies contributing to stem cell research as collaborators, investors or partners are also identified.

    A few of the "real" stem cell 18 companies include:

    -- Ceregene, Inc. (US)

    -- Geron Corporation (US)

    -- Novocell, Inc. (US)

    -- NsGene A/S (Denmark)

    -- ReNeuron Group plc (UK)

    -- StemCells Inc. (US)

    -- ViaCell Inc. (US)
    <companies mentioned>
    Companies Mentioned
    Aastrom Biosciences Inc.
    Advanced Cell Technology Inc.
    Amgen
    Amersham
    AstraZeneca
    Biogen Idec
    BresaGen Ltd.
    Cell Genesys
    Cellartis AB
    Cellular Dynamics International
    Ceregene, Inc.
    Covance
    Cytori Therapeutics, Inc.
    Genentech
    Genesys Inc.
    Genzyme
    Geron Corporation
    Incyte
    Johnson & Johnson
    Layton Bioscience Inc.
    Merck
    Novartis AG
    Novocell, Inc.
    NsGene A/S
    Quintiles
    ReNeuron Group plc
    Schering AG
    Stem Cell Therapeutics Corp.
    StemCells Inc.
    Titan Pharmaceuticals Inc.
    Transition Therapeutics Inc.
    TriStem Corporation
    ViaCell Inc.
    [/quote]

    #2
    Thanks for the post. I see this is only private companies – I’m wondering how many government owned universities/hospitals are working on stem cells which can make a difference. Does anybody know actually how many stem cell centres there are around the world? Approx?

    Comment


      #3
      Originally posted by Leif
      Thanks for the post. I see this is only private companies – I’m wondering how many government owned universities/hospitals are working on stem cells which can make a difference. Does anybody know actually how many stem cell centres there are around the world? Approx?
      Check here for some: http://www.cureparalysisnow.org/foru...dfe1a3afc35cbd
      "it is not necessary to hope in order to persevere" ~ William of Orange

      Comment


        #4
        Sorry - your link would not open Pro-SCNT.

        Comment


          #5
          Dear Leif Hope you will be fine. Never forget you are amongst my favourite CC Members. God bless you. Always smile and live happy.


          Dear Young TriStem is already treating patients here in pakistan and tell some good results too. When i did contact to them they are hopeful for my good recovery as you know i am incomplete with L1 compression. They say that i can regain bladder bowel and sexual function. Though not much confident but still reasonable for recovery.

          I need to know from you is that is TriStem reliable and i should go for treatment? Hope you will advise best. God bless you and keep you happy and healthy longer.

          Jawaid

          Comment


            #6
            Stem Cell Therapies and Regenerative Medicine: Current Applications

            B-153R Stem Cell Therapies and Regenerative Medicine: Current Applications and Future Possibilities

            Steven Edwards, Ph.D.

            Published December 2005
            $3,950.00 for full report (add 15% for PDF version)
            Page and Chapter Pricing Available - Go to "Purchase On-line"
            2002 Version Available
            REPORT HIGHLIGHTS
            • The worldwide market for stem cell, cytokine and growth factor therapies is estimated at $12.7 billion in 2005 and, rising at an average annual growth rate (AAGR) of 10.3%, is expected to reach $20.7 billion in 2010.
            • Nearly 98% of the market is consumed by blood and immune system treatments, a figure that will shrink slightly to 95% in 2010.
            • Revenues worldwide for stem cell, cytokine and growth factor therapies for all other bodily systems are expected to rise at an AAGR of 26.4% to just over $1 billion in 2010.
            • The first off-the-shelf cell therapy approved by the FDA was for wound treatment. Recently, a bone morphogenic protein (BMP) has been approved for the acceleration of spinal fusions.
            Global Forecast of Revenues for Stem Cell and Cytokine Therapies in Regenerative Medicine, 2003-2010
            ($ Billions)

            Source: BCC, Inc.

            INTRODUCTION
            In March 2002, BCC published its first study focused on stem cells and progenitor cell therapy. Since that time, stem cell and regenerative companies have had a difficult time because of a shortage of funding. However, new companies have sprung up, as new research prompts new avenues of exploration.

            The political climate for embryonic stem cells has changed. The Bush Administration maintains a ban in the U.S. on federal funding for research using newly established lines. However, California and Illinois have begun funding this research and others seem likely to follow. The House of Representatives has passed a bill reversing Bush's ban, and the Senate is likely to pass it. Meanwhile, other countries are making embryonic stem cell research a priority. For most of 2005, for instance, it seemed as if South Korean scientists had surpassed the rest of the world in the ability to generate patient-specific embryonic stem cells through nuclear transfer. It now appears that these results were fabricated; respectable peer-reviewed journals were taken in by the hoax because the achievements described were quite feasible, given similar results acheived in animal studies.

            Given these many changes taking place in regenerative medicine, it seems a good time to renew our study of this field. This comprehensive and cohesive technical market research report from BCC is set within the existing regulatory framework and takes into account not only technical accomplishments but also political and financial realities. The study, therefore, establishes the necessary context from which to make rational decisions regarding business decisions in this expanding field.
            SCOPE OF STUDY
            The report contains:
            • An overview that introduces the various kinds of stem cells, gives definitions, and discusses political, regulatory aspects, and the major developments of 2005 including the retraction of previously published South Korean stem cell research results
            • Analysis of applications including current and potential cytokine and cell therapies with forecasts through 2010
            • A discussion of current products as well as many that are still in clinical trials
            • An industry structure analysis including companies in the field and their focus
            • Profiles of individual companies, and includes the names of key officers.

            METHODOLOGY AND INFORMATION SOURCES
            The information reported herein has been gathered from a variety of industry and other sources. The 10K forms and other SEC filings from public companies have been examined along with annual reports, catalogues, and press releases. The World Wide Web is a rich source of information, as almost every commercial concern now has its own Web page. Where appropriate, medical literature and scientific literature have served as a research source.

            We have also gathered statistical information from the U.S. government, the World Health Organization, and private foundations. Armed with the industry and statistical information garnered all of these sources, market participants were interviewed to fill in the gaps.
            ANALYST'S CREDENTIALS
            The author of this report, Steven Edwards, Ph.D., has a broad background in the biological and health sciences, and is well acquainted with advanced technology. He received his doctorate in biology from the University of California, San Diego. His thesis work centered on the expression of murine leukemia virus genes, and he was awarded a National Institutes of Health (NIH) postdoctoral fellowship to study neuroendocrinology at the Salk Institute. Subsequently, Dr. Edwards was a Research Associate at La Jolla Cancer Research Foundation (now Burnham Institute), where he studied developmental regulation of gene transcription in teratocarcinoma cells (cells similar to embryonic stem cells). Later, he was appointed assistant professor in the biochemistry department of Meharry Medical College (Nashville, TN). There he directed a research laboratory studying transcriptional regulation, supported by grants from the American Heart Association and the NIH.

            Dr. Edwards is now a medical industry analyst, and science writer and editor. He has been the editor of several BCC newsletters: Applied Genetics News, Drug Discovery/Technology News, Cell Therapy News, and Nano/Bio Convergence News, and is now editor of Biomolecular Diagnostic News. His journalistic work has also appeared in Massachusetts Institute of Technology's (MIT's) Technology Review, Diabetes Forecast, Genetic Engineering News, and other publications. He is a frequent contributor to RedzoneProfits (Website: www.redzoneprofits.com), an Internet-based investment newsletter that focuses on emerging technology companies.

            Dr. Edwards was the project analyst responsible for the BCC reports B-119 Cell Therapy and Tissue Engineering, Emerging Products (1998); B-127 Microelectronic Medical Implants, Products, Technology and Opportunity (1999); B-143 Bones and Joints: Drugs, Devices, and Regenerative Technologies (2000); Progenitor and Stem Cell Therapy: Current Uses and Future Possibilities (2002); B-162 Biomedical Applications of Nanoscale Devices (2003); and B-192 Beyond Chemotherapy: Battling Cancer with Biotechnology (2004). He is also the author of The Nanotech Pioneers: Where are they taking us?, a book due to be published by Wiley-VCH Verlag GmbH & Co. in January 2006.

            Dr. Edwards has served as vice president for technologies for Phaelixe, Inc., a consulting firm in Denver, CO. He has also consulted for a venture capital company, and has served as program chairman for several nanotech and nanobiotech conferences hosted by BCC. .
            OTHER RELEVANT BCC REPORTS AND PUBLICATIONS

            TABLE OF CONTENTS

            INTRODUCTION
            XVIREASON FOR DOING THE STUDY
            XVISTUDY GOAL AND OBJECTIVES
            XVICONTRIBUTIONS OF THE STUDY AND FOR WHOM
            XVIISCOPE AND FORMAT
            XVIIMETHODOLOGY AND INFORMATION SOURCES
            XVIIIANALYST'S CREDENTIALS
            XVIIIOTHER RELEVANT BCC REPORTS AND PUBLICATIONS
            XIXBCC ONLINE SERVICES
            XXDISCLAIMER
            XXSUMMARY
            XXISummary Table:
            GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS)
            XXIISummary Figure:
            GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS)
            XXIIIOVERVIEW
            1Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
            1GROWTH FACTORS AND CYTOKINES
            1Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
            2Table 2 (CONTINUED)
            3STEM AND PROGENITOR CELLS
            3WORLDWIDE MARKETS FOR REGENERATIVE MEDICINE
            4Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
            5Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
            6Table 5 AGING OF THE U.S. POPULATION
            6CELL THERAPIES AS A SUBSTITUTE FOR TRANSPLANTS
            7THE U.S. MARKET VERSUS THE REST OF THE WORLD
            7The U.S. Market versus the (Continued)
            8Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
            9DISTRIBUTION OF REVENUES AND EFFORT
            10TYPES OF STEM OR PROGENITOR CELLS
            11Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
            12Autologous Cells
            13Allogeneic Cells
            14UMBILICAL CORD BLOOD
            14Table 8 A PARTIAL LIST OF DISEASES TREATED USING CORD BLOOD STEM CELLS
            15EMBRYONIC STEM CELLS
            16Embryonic Stem Cells (Continued)
            17Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
            18Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
            18Table 10 (CONTINUED)
            19Identification of Stem Cells
            19Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
            20Therapeutic Cloning
            20Therapeutic Cloning (Continued)
            21Utility of ES Cells
            22Ethical Considerations
            23Position of the Catholic Church
            24Position of the National Academy of Sciences
            25Politics and Funding for Embryonic Stem Cell Research
            26Politics and Funding for Embryonic Continued)
            27NIH Guidelines
            28NIH Guidelines (Continued)
            29Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
            30Patents
            30GERM CELLS
            31WHAT MAKES A STEM CELL A STEM CELL?
            31CELL-BASED GENE THERAPY
            32U.S. REGULATION
            33DEVICES
            33Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
            34BIOLOGICALS
            35Biologicals (Continued)
            36ORPHAN PRODUCT STATUS
            37INTERNATIONAL ISSUES
            37OFFSHORE CELL-THERAPY TREATMENTS
            38OFFSHORE CELL-THERAPY TREATMENTS (CONTINUED)
            39APPLICATIONS FOR PROGENITOR CELL THERAPIES
            40APPLICATIONS OF REGENERATIVE MEDICINE FOR BLOOD AND THE IMMUNE SYSTEM
            40Figure 1 HEMATOPOIESIS
            41APPLICATIONS OF REGENERATIVE CONTINUED)
            42Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
            43Table 14 (CONTINUED)
            44HARVESTING HEMATOPOIETIC STEM CELLS
            44Bone Marrow
            44Peripheral Blood Progenitor Cell Collection
            45Umbilical Cord Blood
            46Drug-Resistant Hematopoietic Stem Cells
            46PRODUCTS AND SERVICES IN SUPPORT OF HEMATOPOIETIC STEM CELL TRANSFERS
            47Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
            48CYTOKINES FOR STEM CELL THERAPY
            49Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
            50G-CSF and GM-CSF
            50AMD3100
            51Erythropoietins
            51MARKET OPPORTUNITIES FOR REGENERATIVE CYTOKINES
            52Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
            53Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
            53HARVESTING AND STORAGE OF UMBILICAL CORD BLOOD
            54Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
            55Market Opportunities for Umbilical Cord Blood Storage
            56Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
            57Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
            58Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
            58EXPANSION OF STEM CELLS
            58Expansion of Stem Cells (Continued)
            59Market Opportunities for Stem Cell Expansion.
            60Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
            60Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
            61GRAFT-VERSUS-HOST DISEASE
            61IMMUNE DEFICIENCIES
            62Acquired Immunodeficiency Syndrome
            63Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
            64Natural Resistance
            64Current Therapies for AIDS
            65Progenitor Cell Therapies for AIDS
            65Market Opportunities for AIDS Therapies
            66Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
            66SUMMARY: BLOOD AND IMMUNE DISEASES
            67Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
            67Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
            68SKIN
            68SKIN CELL PROGENITORS
            69BURNS
            69ULCERS
            70ULCERS (CONTINUED)
            71MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES
            72MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES (CONTINUED)
            73Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
            74Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
            74BONE
            74BONE FRACTURES
            75Bone Metabolism
            76Current Therapies
            77Cell Therapies for Bone Fractures
            77Growth Factors and Morphogenic Proteins
            78Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
            79Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
            80Market Opportunities for Regenerative Therapies for Fractures and Spinal Fusions
            80Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
            81Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
            81Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
            82Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
            82CARTILAGE
            83Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
            83MENISCUS REPAIR
            83INJURIES OF THE KNEE
            84INTERVERTEBRAL DISC REGENERATION
            85MARKETS FOR CARTILAGE REPAIR
            85Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
            86Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
            87CARDIOVASCULAR SYSTEM
            87CONGESTIVE HEART FAILURE
            88Current Therapies
            88CORONARY HEART DISEASE
            89Current Therapies
            89CELL THERAPIES FOR CHF OR CORONARY DISEASE
            89Cell Therapies for CHF or Coronary Disease (Continued)
            90Cell Therapies for CHF or Coronary Disease (Continued)
            91CARDIAC ARRYTHMIA
            92Current Therapy
            92Cell Therapies
            93MARKET OPPORTUNITIES FOR CARDIOVASCULAR CELL THERAPIES
            93Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
            94TEETH
            95HAIR
            95BRAIN AND NERVOUS SYSTEM
            96NEURAL STEM CELLS
            97LYSOSOMAL STORAGE DISEASES
            97DISORDERS OF THE MYELIN SHEATH
            98SPINAL CORD INJURY
            99Spinal Cord Injury (Continued)
            100STROKE
            101Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
            102PARKINSON'S DISEASE
            103Cell Therapies
            103Cell Therapies (Continued)
            104The Market Opportunities for Regenerative Treatments to Treat Neural Disease
            105EYES
            105EYES (CONTINUED)
            106Market Opportunities
            107LIVER
            108HUMAN CELL THERAPIES
            109Human Cell Therapies (Continued)
            110Markets for Regenerative Therapies for the Liver
            111KIDNEY
            111Potential Cell Therapies for Kidney Disease
            112Market Opportunities for Regenerative Kidney Therapies
            113DIABETES
            113Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79 2003 AND 2025 (THOUSANDS)
            114COMPLICATIONS OF DIABETES
            115Current Treatments
            115Edmonton Protocol
            116STEM CELL THERAPIES
            116Market Opportunities for Regenerative Diabetes Therapies
            117REPRODUCTIVE MEDICINE
            118MARKET OPPORTUNITIES FOR OOCYTE CRYOPRESERVATION
            119Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
            120Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)
            120PRODUCTS USED IN CELL THERAPY AND REGENERATIVE MEDICINE
            121PRODUCTS USED FOR AMPLIFYING, CULTURING, OR TRANSFERRING STEM CELLS
            121AASTROMREPLICELL SYSTEM
            121MYOCATH PERCUTANEOUS DELIVERY SYSTEM
            122PLURIX BIOREACTOR SYSTEM
            123CYTOMATRIX
            123CYTOKINES AND GROWTH FACTORS
            124Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
            124AMD3100
            125ARANESP
            125BMP-7
            126CHRYSALIN
            126CTCE-0214
            126CYT 99 007
            127EPOGEN/PROCRIT
            127INFUSE/INDUCTOS
            128NEULASTA
            128NEUMEGA
            129NEUPOGEN
            129OP-1
            130REGRANEX GEL
            131THYMOSIN BETA FOUR
            131TUMOR GROWTH FACTOR ALPHA
            132LIVING CELL THERAPIES
            132HEMATOPOIETIC AND IMMUNE CELL THERAPIES
            133Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
            133Highly Purified Hematopoietic Stem Cells
            134HGTV-43
            134MP Cells
            135Procord
            136SKIN
            136Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
            136Apligraf
            137Dermagraft
            137EpiCel
            138Hyalograft 3D
            138Laserskin Autograft
            138OrCel
            139CARTILAGE
            139Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
            139Carticel
            139Cartilink
            140Chondrogen
            141Co.Don Chondrotransplant
            141Co.Don Chondrotransplant DISC
            141Hyalograft C
            142ICX-PRO
            142ICX-SKN
            142NEURAL STEM CELLS
            143HuCNS-SC
            143MUSCLE
            143Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
            143Biopace
            143MyoCell
            144Myocell VT
            144Provacel
            145OTHER MESENCHYMAL CELLS
            145Prochymal
            145Tissue Repair Cells - Aastrom Bioscience
            146PANCREAS
            146IxSC-1
            146KIDNEY
            147Renal Assist Device
            147STEM CELL STORAGE
            147BIOARCHIVE STEM CELL SYSTEM
            147CCEL CELLULAR STORAGE FREEZER
            148STRUCTURE OF THE INDUSTRY
            149CYTOKINE AND GROWTH FACTOR COMPANIES
            149Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
            149MARKET SHARES OF CYTOKINE AND GROWTH FACTOR COMPANIES
            150Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
            150PRODUCTS UNDER DEVELOPMENT
            150Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
            151UMBILICAL CORD STEM CELL COMPANIES
            151Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
            151CELL THERAPY COMPANIES
            152Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
            152Table 46 (CONTINUED)
            153Table 46 (CONTINUED)
            154PATENTS
            154PATENTS (CONTINUED)
            155Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
            156Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
            157Table 48 (CONTINUED)
            158Table 48 (CONTINUED)
            159Table 48 (CONTINUED)
            160ATTRITION
            160Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
            161COMPANY PROFILES
            162AASTROM BIOSCIENCES
            162ADERANS RESEARCH INSTITUTE
            162ADVANCED CELL TECHNOLOGY
            163ADVANCED CELL THERAPEUTICS
            164AMGEN
            164ANORMED
            165ATHERSYS
            165BAXTER INTL.
            166BEFUTUR BIOTECHNOLOGIES
            166BIOHEART
            167BIOMATRIX SCIENTIFIC GROUP
            168BIOTISSUE, INC.
            168BIOTISSUE TECHNOLOGIES AG
            168BRAINSTORM CELL THERAPEUTICS
            169CELLARTIS
            170CELL BASED DELIVERY
            170CELLERANT THERAPEUTICS
            171CELLRESEARCH CORP.
            171CELLULAR DYNAMICS
            172CHEMOKINE THERAPEUTICS
            172CO.DON AG
            173CORCELL
            173CORD BLOOD AMERICA
            173CORD BLOOD REGISTRY
            174CYGENICS
            174CORDLIFE PTE, LTD./ CELL SCIENCES PTE, LTD.
            174CYTOMATRIX
            175CRYO-CELL INTL.
            175CYTHERA
            176CYTORI THERAPEUTICS
            176DENTIGENIX, INC.
            177ENCELLE
            177ENZO BIOCHEM
            178EXTENDFERTILITY
            179FIDIA FARMACEUTICI SPA
            179FREZER, INC.
            179GENZYME BIOSURGERY
            180GENVEC
            181GERON
            181HISTOSTEM
            182INTERCYTEX
            182INTERFACE BIOTECH A/S
            183ISLET TECHNOLOGY
            183ISTO TECHNOLOGIES
            184IXION BIOTECHNOLOGY
            185KALEIDOS PHARMACEUTICAL
            185JOHNSON & JOHNSON
            186LIFEBANK CRYOGENICS
            186MEDRA
            187MESOBLAST, LTD.
            187MILTENYI BIOTEC GMBH
            188MORPHOGENESIS
            188NEOSTEM
            189NEPHROS THERAPEUTICS
            189NEURALSTEM BIOPHARMACEUTICALS
            190NEURONYX
            190NOVARTIS INTERNATIONAL AG
            191NS GENE A/S
            191ODONTIS
            192ORGANOGENESIS
            192ORTEC INTL.
            193ORTHOLOGIC
            193OSIRIS THERAPEUTICS
            194PHARMA FRONTIERS
            194PHARMASTEM THERAPEUTICS
            195PLURISTEM LIFE SYSTEMS
            195PRIMEGEN BIOTECH, LLC
            196PROGENITOR CELL THERAPY
            196PRONEURON BIOTECHNOLOGIES
            197REGENERX BIOPHARMACEUTICALS
            197RENEURON
            198SANERON CCEL THERAPEUTICS, INC.
            198STEMCELLS, INC.
            199STEMCELL PHARMA, INC.
            199STEM CELL SCIENCES
            200STEM CELL THERAPEUTICS CORP.
            200STEM CELL THERAPY INTL.
            201THERMOGENESIS
            202TISSERA
            202U.S. BIODEFENSE, INC.
            202VESTA THERAPEUTICS
            203VIACELL
            203WICELL RESEARCH INSTITUTE
            204APPENDIX
            205GLOSSARY OF TERMS AND ABBREVIATIONS
            205GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
            206GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
            207GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
            208GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
            209GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
            210GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
            211GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
            212GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED)
            213 LIST OF TABLES

            Summary Table:
            GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS)
            XXIITable 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
            1Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
            2Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
            5Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
            6Table 5 AGING OF THE U.S. POPULATION
            6Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
            9Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
            12Table 8 A PARTIAL LIST OF DISEASES TREATED USING
            15CORD BLOOD STEM CELLS
            15Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
            18Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
            18Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
            20Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
            30Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
            34Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
            43Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
            48Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
            50Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
            53Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
            55Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
            57Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
            58Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
            60Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
            64Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
            66Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
            67Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
            74Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
            79Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
            80Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
            81Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
            81Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
            82Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
            83Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
            86Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
            94Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
            102Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79, 2003 AND 2005 (THOUSANDS)
            114Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
            120Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
            124Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
            133Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
            136Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
            139Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
            143Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
            149Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
            150Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
            151Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
            151Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
            152Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
            156Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
            157Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
            161 LIST OF FIGURES

            Summary Figure:
            GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS)
            XXIIIFigure 1 HEMATOPOIESIS
            41Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
            53Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
            58Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
            61Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
            68Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
            74Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
            82Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
            87Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)
            120

            Comment


              #7
              Jawaid,

              I don't know enough about Tristem to comment definitively. I have not seen any evidence that they have any evidence to back up claims that their treatments will be beneficial for spinal cord injury.

              Wise.

              Originally posted by Jawaid
              Dear Leif Hope you will be fine. Never forget you are amongst my favourite CC Members. God bless you. Always smile and live happy.


              Dear Young TriStem is already treating patients here in pakistan and tell some good results too. When i did contact to them they are hopeful for my good recovery as you know i am incomplete with L1 compression. They say that i can regain bladder bowel and sexual function. Though not much confident but still reasonable for recovery.

              I need to know from you is that is TriStem reliable and i should go for treatment? Hope you will advise best. God bless you and keep you happy and healthy longer.

              Jawaid

              Comment


                #8
                Dear Dr. Young

                Can you tell me something about the treatments of TriStem? Their procedure is called Retrodifferentation i think. What is this? Are they using Umbilical Cord Cells or any other type of cells? How much this way of treatment can be fruitful for Spinal injury?

                Jawaid

                Comment

                Working...
                X